`(TRACK 1)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`William H. McKenna et al.
`
`Application No.: 14/729,660
`
`Filed: June 3, 2015
`
`Customer No. 06980
`
`Confirmation No.: 2426
`
`Art Unit: 1642
`
`For: TAMPERRESISTANTDOSAGEFORMS
`
`Examiner: AKHOON, KAUSER M.
`
`AMENDMENT AFTER FINAL
`
`MS Amendment
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Dear Commissioner:
`
`Please amend this U.S. patent application as follows.
`
`Amendments to the Claims begin on page 2 of this paper.
`
`Remarks/arguments begin on page 8 of this paper.
`
`28579517vl
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`AMENDMENTS TO THE CLAIMS
`
`The following listing of claims replaces all previous claims, and listings of claims, in the
`application.
`
`1-169. (Cancelled)
`
`(Currently Amended) A method of treating pain comprising administering to a
`170,
`patient in need thereof a pharmaceutical tablet comprising:
`(1) at least a first compression shaped and then air cured matrix, wherein said
`curing is without compression by heated air having a temperature of at least about 62 ° C
`for a duration of at least about 5 minutes, said matrix comprising oxycodone or a
`pharmaceutically acceptable salt thereof in combination with at least one high molecular
`weight polyethylene oxide having, based on rheological measurements, an approximate
`molecular weight selected from the group consisting of 4,000,000, 7,000,000, and a
`combination thereof, and optionally further comprising at least one low molecular weight
`polyethylene oxide having, based on rheological measurements, an approximate
`molecular weight of less than 1,000,000;
`(2) optionally a second air cured matrix compnsmg oxycodone or a
`pharmaceutically acceptable salt thereof in combination with at least one low molecular
`weight polyethylene oxide having, based on rheological measurements, an approximate
`molecular weight of less than 1,000,000; and
`(3) optionally a coating,
`wherein in said tablet:
`(i) said oxycodone or pharmaceutically acceptable salt thereof is provided in a
`dose selected from the group consisting of 10 mg, 15, mg, 20 mg, and 30 mg;
`the total combined weight of said low molecular weight polyethylene oxide, if
`present, and said high molecular weight polyethylene oxide is at least 79 % by weight of
`the total weight of said tablet, excluding the weight of any coatings; and
`
`28579517vl
`
`2
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`said low molecular weight polyethylene oxide, if present, is at leastl 0% by weight
`of the total weight of said uncoated tablet, excluding the weight of any coatings;or
`(ii) said oxycodone or pharmaceutically acceptable salt thereof is provided in a
`dose selected from the group consisting of 40 mg, 60 mg, and 80 mg;
`the total combined weight of said low molecular weight polyethylene oxide, if
`present, and said high molecular weight polyethylene oxide is at least 65 % by weight of
`the total weight of said tablet, excluding the weight of any coatings; and
`said low molecular weight polyethylene oxide, if present, is at least 10 % by
`weight of the total weight of said tablet, excluding the weight of any coatings; and
`said tablet provides a dosage form for twice-daily extended release administration
`of oxycodone or pharmaceutically acceptable salt thereof
`
`(Previously Presented) A method as defined in claim 170, wherein said
`171.
`oxycodone or pharmaceutical salt thereof comprises at least 5% by weight, based upon the total
`weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 170, wherein each shaped
`172.
`and cured matrix has been cured by heated air having a temperature of about 62° C to about 90 °
`C for a duration of about 15 minutes to about 10 hours, and then is subsequently cooled.
`
`(Previously Presented) A method as defined in claim 172, wherein said heated air
`173.
`temperature is from about 65° C to about 90° C, said duration is about 15 minutes to about 8
`hours, and said cooling comprises exposure to an air temperature of less than about 62 ° C.
`
`(Previously Presented) A method as defined in claim 170, wherein said shaped
`174.
`tablet is coated at least one of before or after being cured.
`
`(Previously Presented) A method as defined in claim 173, wherein one or both of
`175,
`said first matrix and second matrix further comprise a coating.
`
`28579517vl
`
`3
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`(Previously Presented) A method as defined in claim 170, wherein, said second
`176.
`matrix is not present, the dosage amount of oxycodone is selected from 10 mg, 15, mg, 20 mg,
`and 30 mg, and the total combined weight of said high and low molecular weight polyethylene
`oxide is at least 79 %by weight of the total weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 170, wherein, said second
`177.
`matrix is not present, the dosage amount of oxycodone is selected from 40 mg, 60 mg, and 80
`mg, and the total combined weight of said high and low molecular weight polyethylene oxide is
`at least 65 % by weight of the total weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 176, wherein said low
`178.
`molecular weight polyethylene oxide is not present.
`
`(Previously Presented) A method as defined in claim 177, wherein said low
`179.
`molecular weight polyethylene oxide is not present.
`
`(Previously Presented) A method as defined in claim 174, wherein the total
`180.
`combined weight of said high and low molecular weight polyethylene oxide is at least 65 % by
`weight, based upon the total weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 174, wherein the total
`181.
`combined weight of said high and low molecular weight polyethylene oxide is at least 80 % by
`weight, based upon the total weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 174, wherein the total
`182.
`combined weight of said high and low molecular weight polyethylene oxide is at least 85 % by
`weight, based upon the total weight of said uncoated tablet.
`
`28579517vl
`
`4
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`(Previously Presented) A method as defined in claim 174, wherein the total
`183.
`combined weight of said high and low molecular weight polyethylene oxide is at least 90 % by
`weight, based upon the total weight of said uncoated tablet.
`
`(Previously Presented) A method as defined in claim 174, wherein said tablet
`184.
`further comprises magnesium stearate.
`
`(Previously Presented) A method as defined in claim 184, wherein said tablet
`185.
`further comprises butylated hydroxytoluene.
`
`(Previously Presented) A method as defined in claim 184, wherein said tablet
`186.
`further comprises at least one of lactose, microcrystalline cellulose and hydroxypropyl cellulose.
`
`(Previously Presented) A method as defined in claim 170, wherein said tablet,
`187.
`when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N;
`and (ii) a penetration depth to crack distance of at least 1.0 mm.
`
`(Previously Presented) A method as defined in claim 170, wherein said tablet can
`188.
`be flattened to a thickness that is no more than about 60% of the initial tablet thickness without
`breaking; and said flattened tablet swells upon exposure to water or ethanol.
`
`(Previously Presented) A method according to claim 170, wherein, after a
`189.
`plurality of at least 100 of the same tablets are stored at 40° C and 75% relative humidity for at
`least 3 months, a set of at least ten of said stored tablets, on average, when measured in a USP
`Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 o
`C., in the absence of an added stabilizer, release an amount of said oxycodone or pharmaceutical
`salt thereof, after 1 hour, 4 hours, and 12 hours, that deviates from an initial dosage amount of
`said oxycodone or pharmaceutical salt thereof by no more than about 10% points.
`
`28579517vl
`
`5
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`(Previously Presented) A method as defined m claim 172, wherein said air
`190.
`temperature during curing exhibits a plateau profile.
`
`(Previously Presented) A method as defined m claim 173, wherein said air
`191.
`temperature during curing exhibits a plateau profile.
`
`(Previously Presented) A method as defined in claim 172, wherein said air
`192.
`temperature during curing exhibits a parabolic or triangular profile.
`
`(Previously Presented) A method as defined in claim 173, wherein said air
`193.
`temperature during curing exhibits a parabolic or triangular profile.
`
`(Previously Presented) A method as defined in claim 172, wherein curing is by
`194.
`convection and said air temperature is measured as a mean exhaust temperature of a convection
`curing device.
`
`(Previously Presented) A method as defined in claim 173, wherein curing is by
`195.
`convection and said air temperature is measured as a mean exhaust temperature of a convection
`curing device.
`
`(Previously Presented) A method as defined in claim 188, wherein said tablet,
`196.
`when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N;
`and (ii) a penetration depth to crack distance of at least 1.0 mm.
`
`(Previously Presented) A method as defined in claim 173, wherein curing is by
`197.
`convection and said air temperature is measured as a mean exhaust temperature of a convection
`curing device.
`
`28579517vl
`
`6
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`(Previously Presented) A method as defined in claim 170 wherein said cured
`198.
`shaped tablet has a density that is at least about 1 % lower than the density of said shaped tablet
`prior to curing.
`
`(Previously Presented) A method as defined in claim 173 wherein said cured
`199.
`shaped tablet has a density that is at least about 1 % lower than the density of said shaped tablet
`prior to curing.
`
`28579517vl
`
`7
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`
`
`Docket No.: 241957.000596
`(TRACK 1)
`
`Remarks
`
`This Amendment is in response to the Final Office Action dated April 8, 2016. Claims
`170-199 are pending. The previous rejections under 35 U.S.C. § 112 and § 102 have been
`withdrawn. The previous§ 103 obviousness rejection has been maintained.
`Claim 170 is amended. The amendment is supported by the Specification and does not
`present new matter.
`Terminal Disclaimers have been submitted.
`The Applicant acknowledges the courtesies extended by the Examiner and her Supervisor
`at the Interview on May 26, 2016. The pending rejections and the prior art relied upon by the
`Examiner were discussed. As suggested to the Applicant at the Interview, independent claim
`170 is now amended to further clarify that curing occurs "without compression." The Examiner
`indicated that this amendment would place the claims in condition for allowance.
`
`Conclusion
`This application is believed to be in condition for allowance. If any issues remain that
`may be addressed by an Examiner's amendment or a supplementary amendment, or if the
`Examiner has any concerns that would benefit from an interview with Applicant's representative,
`the Examiner is respectfully requested to contact the undersigned.
`The Commissioner is authorized to charge any deficiency or credit any excess in the fees
`to Deposit Account No. 20-1507 of Customer No. 06980.
`
`Respectfully submitted,
`TROUTMAN SANDERS LLP
`/Joseph R. Robinson/
`Joseph R. Robinson
`Registration No. 33,448
`
`Please recognize our Customer No. 06980
`as our correspondence address.
`
`Date: June 3, 2016
`
`8
`
`875 Third Avenue
`New York, NY 10022
`Phone: 212-704-6000
`Facsimile: 212-704-6288
`
`28579517vl
`
`KASHIV1039
`IPR of Patent No. 9,492,393
`
`